5 Key Takeaways
-
1
Selective laser trabeculoplasty (SLT) reduces the medication burden on glaucoma patients and improves treatment adherence.
-
2
SLT has shown better clinical outcomes and stability in disease management compared to traditional eye drops.
-
3
The LiGHT trial demonstrated that 74.2% of SLT-treated eyes required no additional eye drops to maintain target IOP.
-
4
Implementing SLT in clinical practice can enhance efficiency and reduce patient visits related to medication issues.
-
5
SLT is a quick, minimally invasive procedure that can be performed in-office, requiring minimal postoperative care.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.